DCTH

Business Context and Reporting Period

Company: Delcath Systems, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2009
Business Overview: Delcath is a development-stage company focused on the Delcath Percutaneous Hepatic Perfusion (PHP) System, a minimally invasive platform designed to deliver high-dose chemotherapy directly to the liver while filtering systemic exposure. The company has no commercial revenue and is currently conducting a Phase III clinical trial for metastatic melanoma in the liver and a multi-arm Phase II trial for other hepatic malignancies. The product requires FDA approval as a combination drug/device product.

Key Financial Metrics

Note: All figures in millions unless otherwise noted. The company has no debt obligations listed in the balance sheet liabilities, but carries significant derivative liabilities related to warrant issuances.

Material Changes vs. Prior Period

• Net Loss Increase: Net loss increased by 221% to $22.06 million in 2009 compared to $6.86 million in 2008. This was driven by a $5.47 million increase in operating costs and a $9.67 million swing in derivative instrument expense (from income in 2008 to expense in 2009).
• Derivative Liability: A significant non-cash expense of $8.57 million was recorded due to the mark-to-market adjustment of warrants issued in 2007 and 2009. The total derivative liability on the balance sheet grew from $0.45 million in 2008 to $11.21 million in 2009.
• Liquidity Improvement: Cash and cash equivalents increased significantly from $6.94 million to $35.49 million, primarily due to a November 2009 public offering that raised approximately $32.5 million in net proceeds.
• R&D Acceleration: Research and development expenses rose 79% to $9.64 million, reflecting the completion of enrollment in the Phase III clinical trial and the addition of new clinical centers.

Guidance, Outlook, and Risks

• Clinical Progress: As of October 20, 2009, the company completed enrollment of all 92 patients in its Phase III trial for metastatic melanoma. Data analysis began in February 2010. The company expects to submit an FDA application by mid-2010.
• Capital Resources: Management believes current capital resources are sufficient to fund operations through 2010. However, the company anticipates needing additional capital prior to commercialization to fund manufacturing, marketing, and further development.
• Strategic Alliances: In February 2010, the company signed its first distribution agreement with Chi-Fu Trading Co., Ltd. for Taiwan and potentially Singapore. It is also pursuing partners for European (CE mark) and Asian markets.
• Key Risks:
  • Regulatory Approval: No revenue can be generated without FDA approval of the combination product (device and drug).
  • Liquidity: Continued losses may exhaust capital resources if additional financing is not available on acceptable terms.
  • Derivative Volatility: The company's net loss is heavily impacted by non-cash mark-to-market adjustments on warrants, which depend on stock price volatility.
  • Reimbursement: There is no assurance that third-party payers (Medicare, private insurers) will reimburse the procedure post-approval.

Investor Verification Checklist

• Phase III Trial Data: Verify the timing and results of the data analysis for the Phase III melanoma trial, as this is the primary catalyst for FDA submission.
• Derivative Liability Impact: Monitor the fair value of outstanding warrants (2007 and 2009 issuances), as fluctuations in stock price will cause significant non-cash volatility in reported net loss.
• Cash Burn Rate: Assess the runway of the $35.5 million cash balance against the projected costs of the new manufacturing facility in Queensbury, NY, and the FDA submission process.
• Regulatory Milestones: Track the status of the Special Protocol Assessment (SPA) with the FDA and the timeline for the New Drug Application (NDA) submission.
• International Partnerships: Evaluate the progress of the Chi-Fu Trading agreement and the pursuit of CE mark approval for the European market.